Chemed: Game Over
Citron details the breaking news defining the looming regulatory and litigation threat at Chemed (NYSE:CHE) the analysts won’t identify.
Citron is very familiar with Medicare fraud from the Amedisys days. Here we provide links to the breaking news, including the pivotal case documents the company should disclose and the analysts haven't mentioned.
Price target : $15.00.
( As always, Citron recommends you download the PDF, and right-click to open the relevant links.)